Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series

被引：1
|
作者：
Gupta, Ashish [1 ,4 ]
Jatwani, Karan [1 ]
Gupta, Kush [2 ]
Qiu, Jingxin [3 ]
Dy, Grace K. [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY USA
[2] Univ Massachusetts, Dept Med, Med Sch Baystate, Springfield, MA USA
[3] Roswell Park Comprehens Canc Ctr, Dept Pathol, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY 14203 USA
来源：
JCO PRECISION ONCOLOGY | 2023年 / 7卷
关键词：
D O I：
10.1200/PO.22.00476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
    Kato, Yuki
    Kato, Yasuhiro
    Minegishi, Yuji
    Suzuki, Takahiro
    Nakamichi, Shinji
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Kubota, Kaoru
    Terasaki, Yasuhiro
    Seike, Masahiro
    Gemma, Akihiko
    ONCOTARGETS AND THERAPY, 2021, 14 : 5315 - 5319
  • [22] HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient
    Wang, Mingwei
    Zhang, Ding
    Wang, Guoqiang
    Xia, Jing
    Chen, Shiqing
    Li, Shuguang
    Xu, Yinhua
    Wang, Qianlan
    Li, Wei
    LUNG CANCER, 2021, 151 : 106 - 107
  • [23] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
    Planchard, D.
    Kim, H. R.
    Suksombooncharoen, T.
    Li, R.
    Samol, J.
    Runglodvatana, Y.
    Lee, K. -Y.
    Chang, G. -C.
    Kowalski, D.
    Han, J. -Y.
    Saw, S.
    Huang, Y.
    Sookprasert, A.
    Nakajima, E.
    Alfon, J.
    Chang, Y. -T.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S46 - S47
  • [25] Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
    Giulio Metro
    Sara Baglivo
    Riccardo Moretti
    Guido Bellezza
    Angelo Sidoni
    Fausto Roila
    Oncology and Therapy, 2020, 8 : 341 - 350
  • [26] HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report
    Guren, Ali Kaan
    Kocaaslan, Erkam
    Agyol, Yesim
    Majidova, Nargiz
    Sever, Nadiye
    Erel, Pinar
    Celebi, Abdussamet
    Arikan, Rukiye
    Isik, Selver
    Sari, Murat
    Bayoglu, Ibrahim Vedat
    Koestek, Osman
    ANTI-CANCER DRUGS, 2024, 35 (08) : 769 - 773
  • [27] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (31) : 4852 - +
  • [28] Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report
    He, Xincheng
    Hou, Lei
    Bai, Jun
    Sun, Chao
    Wang, Dongjie
    An, Gaili
    ANTI-CANCER DRUGS, 2024, 35 (01) : 101 - 108
  • [29] Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
    De Langen, Joop
    Kuiper, Justine Leonie
    Thunnissen, Erik
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Smit, Egbert F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Smit, Egbert F.
    Felip, Enriqueta
    Uprety, Dipesh
    Nagasaka, Misako
    Nakagawa, Kazuhiko
    Rodriguez, Luis Paz-Ares
    Pacheco, Jose M.
    Li, Bob T.
    Planchard, David
    Baik, Christina
    Goto, Yasushi
    Murakami, Haruyasu
    Saltos, Andreas
    Pereira, Kaline
    Taguchi, Ayumi
    Cheng, Yingkai
    Yan, Qi
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    LANCET ONCOLOGY, 2024, 25 (04): : 439 - 454
12345